Phased implementation of pathogen-reduced platelets in a health system facilitates increased manufacturing at the blood center.

CONCLUSION: Phased implementation is a practical and ethical way to introduce PR PLTs in a health system and facilitates scalability at the blood center. Widespread availability of PR products may require collective action and can be increased by optimization strategies during manufacturing. PMID: 31408203 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31408203?dopt=Abstract

Source: Transfusion - August 12, 2019 Category: Hematology Authors: Allen ES, Vincent C, Reeve DA, Kopko PM Tags: Transfusion Source Type: research